<unk> , known as FibroSure in the US, is a biomarker test that uses the results of six blood serum tests to generate a score that is correlated with the degree of liver damage in people with a variety of liver diseases.<unk>  has the same prognostic value as a liver biopsy. FibroSure uses quantitative results of five serum biochemical markers, α2-macroglobulin, haptoglobin, apolipoprotein A1, bilirubin, gamma glutamyl transpeptidase (GGT), with a patient’s age and gender to generate a measure of fibrosis and necroinflammatory activity in the liver.<unk>  has been evaluated in relation to liver biopsy (the current reference standard in liver disease assessment) in people with hepatitis C, hepatitis B, alcoholic liver disease, and non-alcoholic fatty liver disease. They are most useful for cirrhosis and less useful for other stages of liver disease. By 2008 it had been used in over 350,000 patients. In 2006, the French National Authority for Health recommended the use of<unk>  as one of a number of first-line assessment tool for fibrosis with untreated chronic hepatitis C.
FibroTest
Fibrinogen uptake test
Ecarin clotting time
Fibrin degradation product
Thrombin time
Thrombin generation assay
Prothrombin time
Coagulation activation marker